GE Healthcare to acquire radiopharmaceutical company for $945M in cash
GE Healthcare announced Oct. 5 a definitive agreement to acquire SOFIE Biosciences, a Positron Emission Tomography radiopharmaceutical company, for $945 million in cash.  SOFIE Biosciences manufactures PET radiopharmaceuticals including Flyrcado (flurpiridaz F18 injection), which the FDA approved in 2024 to detect myocardial ischemia and infarction. Trilantic North America currently owns SOFIE.  GE Healthcare and Trilantic […] The post GE Healthcare to acquire radiopharmaceutical...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.